GSK Spreads Smoking-Cessation Aids To Countries Serious About Quitting
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline plans to introduce its smoking-cessation products to 800 million people over the next four years in countries working to reduce smoking among their populations
You may also be interested in...
Tobacco Oversight Looks More Likely, But Is It Bad For FDA’s Health?
The likelihood of Congress handing FDA responsibility for regulating tobacco has ignited debate over whether the new purview would distract an already struggling agency from its mission
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”